Access to anti-retroviral drugs, male in Denmark

Denmark: Access to anti-retroviral drugs, male was 93.0% in 2023. ▲ Rising

Latest (2023)
93.0%
Change on year
up 1.1%
World rank
7th
of 141 countries
All-time high
93.0%
in 2023
All-time low
43.0%
in 2000
Years of data
24
2000–2023

Access to anti-retroviral drugs, male in Denmark, 2000–2023

0204060801002000201120232000: 43 %2001: 43 %2002: 44 %2003: 46 %2004: 48 %2005: 49 %2006: 51 %2007: 52 %2008: 57 %2009: 61 %2010: 65 %2011: 69 %2012: 73 %2013: 74 %2014: 79 %2015: 80 %2016: 81 %2017: 83 %2018: 85 %2019: 87 %2020: 89 %2021: 91 %2022: 92 %2023: 93 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2023, access to anti-retroviral drugs, male in Denmark stood at 93.0%. That is the highest value across all 24 years on record.

That represents a change of up 1.1% on the previous year and up 25.7% over ten years.

Over the whole period, access to anti-retroviral drugs, male in Denmark peaked at 93.0% in 2023 and was at its lowest, 43.0%, in 2000.

That places Denmark 7th out of 141 countries with data for 2023, putting it in the top 10%.

The long-run direction has been consistently rising across the 24 years of available data.

Access to anti-retroviral drugs, male in Denmark, year by year

Annual values for Access to anti-retroviral drugs, male (%) in Denmark, 2000 to 2023.
Year % Change
2000 43.0%
2001 43.0% +0.0%
2002 44.0% +2.3%
2003 46.0% +4.5%
2004 48.0% +4.3%
2005 49.0% +2.1%
2006 51.0% +4.1%
2007 52.0% +2.0%
2008 57.0% +9.6%
2009 61.0% +7.0%
2010 65.0% +6.6%
2011 69.0% +6.2%
2012 73.0% +5.8%
2013 74.0% +1.4%
2014 79.0% +6.8%
2015 80.0% +1.3%
2016 81.0% +1.2%
2017 83.0% +2.5%
2018 85.0% +2.4%
2019 87.0% +2.4%
2020 89.0% +2.3%
2021 91.0% +2.2%
2022 92.0% +1.1%
2023 93.0% +1.1%

Averages by decade

DecadeAverage LowestHighest Years
2000s 49.4% 43.0% 61.0% 10
2010s 77.6% 65.0% 87.0% 10
2020s 91.2% 89.0% 93.0% 4

Countries ranked near Denmark

  1. 4 Rwanda 95.0% compare
  2. 4 Sweden 95.0% compare
  3. 4 Zambia 95.0% compare
  4. 7 Ethiopia 93.0% compare
  5. 7 Saudi Arabia 93.0% compare
  6. 7 United Kingdom of Great Britain and Northern Ireland 93.0% compare

See the full ranking of 160 places →

More gender data for Denmark

All data for Denmark →

Frequently asked questions

What is access to anti-retroviral drugs, male in Denmark?
Access to anti-retroviral drugs, male in Denmark was 93.0% in 2023, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, male recorded in Denmark?
The highest recorded value was 93.0% in 2023.
What is the lowest access to anti-retroviral drugs, male recorded in Denmark?
The lowest recorded value was 43.0% in 2000.
How does Denmark rank for access to anti-retroviral drugs, male?
Denmark ranks 7th out of 141 countries with data for 2023.
Is access to anti-retroviral drugs, male rising or falling in Denmark?
Over the last ten years it is up 25.7%. The long-run trend across the full record is rising.
Where does this Denmark data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 24 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, male in Denmark. Statizoid, drawing on UNAIDS estimates. Retrieved 07 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/denmark/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/denmark/">Access to anti-retroviral drugs, male in Denmark</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.